Remove tag molecules
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Rather than investing more in R&D, most pharma companies feel its more cost-effective to buy small biotech companies developing unique molecules that can find a market niche.

Pharma 210
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. cancer agent or disease-relevant toxin.

article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies, a strong scientific interpretation and orientation is essential. Teams are stepping up to this challenge, actively shaping the trajectory of new interventions right from their inception.

Medical 52
article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Across the world, to varying degrees, the regulations were written in an era of small molecules and biologics. AZ: How can regulators ensure that they nurture future innovations in the field?

article thumbnail

Advanced therapies and the high-profile pricing dilemma

pharmaphorum

Previously, the discovery of small molecule treatments had been the priority, with their development and manufacturing process being an established formula. This is how small molecule treatments typically work and, as a result, this was how the entire industry formed over the last century to create a profitable enterprise.

Medicine 130
article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

A new wave of medicines has emerged in recent years to supplement the well-established small and large molecule platforms that have historically dominated the market. It is vital to ensure adequate exposure in the target tissue, tailoring product performance to patient needs and the properties of the molecule and target.